WHC est encore en dévelopement. Lisez ceci pour comprendre notre approche.
depiction of HPHUVLMMVZITSG-UHFFFAOYSA-N.svg
isomerdesign

Etiracetam

Vérifier sur isomerdesign

isomerdesign

Levetiracetam

Vérifier sur isomerdesign

pubchem

Levetiracetam

Vérifier sur pubchem

drugmap

Levetiracetam

Vérifier sur drugmap

wiki

Etiracetam

Vérifier sur wiki

wiki

Levetiracetam

Vérifier sur wiki

Data

InChI: InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)

Synonymes: LEVETIRACETAM [MI],(S)-2-(2-Oxo-1-pyrrolidinyl)butyramide,SR-01000759400,LEVETIRACETAM ACTAVIS GROUP, Levetiracetam In Sodium Chloride,ucb L059,(S)-Levetiracetam,Levetiracetamum,AB00639945-06,LEVETIRACETAM [VANDF],AC-1479,AKOS015841981,(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, UCB-L 059,UCB 22059, ucb L060,SR-01000759400-4,Levetiracetam [USAN:USP:INN:BAN],LEVETIRACETAM [ORANGE BOOK],NCGC00186028-01, Levetiracetamum,MLS006010215,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam,AM20070676,LEVETIRACETAM [USP-RS],BCP11856, Ucb L060,Levetiracetam actavis,E keppra (TN),MLS001424069,N03AX14, Etiracetam, S-isomer,HSDB 7528,HY-B0106,(S)-2-(2-oxopyrrolidin-1-yl)butyramide, UCB-22059,NSC760119,Levetiracetam- Bio-X,SCHEMBL118843, Levetriacetam, Levetiracetamum [INN-Latin],Keppra XR,matever,Levroxa,BL164623,Levetiracetam [INN],HMS2089L20,(S)-2-(2-Oxopyrrolidin-1-yl)butanamide,Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material,UNII-44YRR34555,Levesam 500, Keppra,Levetiracetam,UCB-22059,(-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide,E Keppra,GTPL6826,AB00639945_08,Elepsia XR,Levetiracetam, >=98% (HPLC),HMS2051D07,Z1255435426,LEVETIRACETAM [MART.],HMS3713P16,(-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE,LEVETIRACETAM [EMA EPAR],D00709,Pharmakon1600-01502265,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-, (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,AB00639945_07,NSC-760119, (S)-2-(2-Oxopyrrolidin-1-yl)butanamide,MFCD03265610,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, United States Pharmacopeia (USP) Reference Standard,ACT02712,Levetiracetam (JAN/USP/INN),Levetiracetamum [INN-Latin],MLS000759403,LEVETIRACETAM RATIOPHARM,NC00178,NSC 760119, SIB-S1,Levetiracetam accord,Etiracetam levo-isomer,L-059,LEVETIRACETAM [HSDB], 44YRR34555,(S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE, Levetiractam,LEVETIRACETAM [EP IMPURITY], Etiracetam levo-isomer,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,STL388027,KS-1176,SDCCGSBI-0633760.P001,Tox21_500835,Levetiracetam In Sodium Chloride,Levetiracetam, European Pharmacopoeia (EP) Reference Standard,Elepsia, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, analytical standard,DB01202,SW197558-3,44YRR34555,CCG-100928, Levetiracetam [INN],Levetiracetam hospira,767L282, Keppra XR,LEVETIRACETAM [USP IMPURITY], 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,,(s)-2-(2-oxopyrrolidin-1-yl) butyramide,Levetiracetam solution,102767-28-2,DTXSID9023207,Levipil,Levetiracetame,Leviteracetam,ZINC1547851,Keppra (TN),BIDD:GT0242,LP00835,(2S)-(2-Oxopyrrolidin-1-yl)butyramide, Keppra (TN),HMS3884O11, Levroxa,LEVETIRACETAM [EP MONOGRAPH],CHEMBL1286,LEVETIRACETAM [USAN],s1356,SMR000466303,NCGC00186028-13,Levetiracetam sun,CS-1854, (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,LEVETIRACETAM [JAN],Keppra,BDBM50422542,UCB-L 059,ALBB-027275,UCB-L059,HMS3262H11,NCGC00261520-01,Torleva,LEVETIRACETAM [USP MONOGRAPH], ucb L059, Keppra, L-059, Leviteracetam,SIB-S1,Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,C07841, CHEBI:6437, UCB-L059,AGB-101, Keppra, Keppra XR),Levetiracetam,(S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-, Spritam,Levetiracetam 1.0 mg/ml in Methanol,EN300-244575,L0234, Torleva,Levetiracetam teva,A800616,Etiracetam, UNII-44YRR34555,CHEBI:6437,Q-201292,SR-01000759400-5,HMS2235I18,Spritam,LEVETIRACETAM [WHO-DD]


Estimated data

Solubility: -0.449 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 47.8% (prediction based on www.mdpi.com)

Similitudes

Voici une série de comparaisons visant à comprendre les propriétés de ce composé. Ce site est encore très expérimental et fait l'objet d'un développement actif. Veuillez vous référer à notre série d'articles d'articles pour bien comprendre notre approche et ses limites. Ces informations sont données à titre indicatif et ne doivent pas être interprétées comme des conseils médicaux.